Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,751 questions in 147 reviews · Pain, Palliative and Supportive Care
current versionsNo studies 361 · 20.6%Ungraded 87 · 5%Very low 625 · 35.7%Low 367 · 21%Moderate 232 · 13.2%High 79 · 4.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Sumatriptan 50 mg or 85 mg plus naproxen 500 mg vs placebo Sustained headache relief during the 24 h post dose for moderate or severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults (2016) · Cochrane | no estimate extracted | NR | High |
Sumatriptan 50 mg or 85 mg plus naproxen 500 mg vs placebo At least 1 AE during treatment for moderate to severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults (2016) · Cochrane | no estimate extracted | NR | Moderate |
Sumatriptan 50 mg or 85 mg plus naproxen 500 mg vs placebo At least 1 AE during treatment for mild baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults (2016) · Cochrane | no estimate extracted | NR | Moderate |
Sumatriptan 50 mg or 85 mg plus naproxen 500 mg vs placebo Serious AE (all levels of baseline pain) · adults with migraine headache ‐ moderate or severe and mild baseline pain Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults (2016) · Cochrane | no estimate extracted | NR | No studies |
Morphine vs placebo Pain intensity VAS score0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 7 studies · 297 participants | Low |
Morphine vs bupivacaine Adverse eventsPercentage of participants with any adverse event · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | RR 0.68 [0.09, 5.17] | 4 studies · 210 participants | Moderate |
Morphine vs NSAIDs Pain intensity VAS score0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 2 studies · 80 participants | Very low |
Morphine vs NSAIDs Pain intensity VAS score0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 2 studies · 80 participants | Low |
Morphine vs NSAIDs Pain intensity VAS score0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 2 studies · 80 participants | Low |
Morphine vs NSAIDs Analgesia durationtime duration from the end of surgery to the time of first analgesic consumption. Scale from: 0 to 100. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 1 study · 50 participants | Low |
Morphine vs NSAIDs Adverse eventsPercentage of participants with any adverse event · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | RR 0.75 [0.19, 3.04] | 3 studies · 120 participants | Moderate |
Intervention NR Pain intensity VAS score 1 mg morphine vs 2 mg morphine0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 2 studies · 105 participants | Low |
Intervention NR Pain intensity VAS score1 mg morphine vs 2 mg morphine 0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 2 studies · 105 participants | Low |
Intervention NR Pain intensity VAS score1 mg morphine vs 2 mg morphine 0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 1 study · 45 participants | Low |
Intervention NR Analgesia duration 1 mg morphine vs 2 mg morphineTime duration from the end of surgery to the time of first analgesic consumption · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 1 study · 60 participants | Moderate |
Morphine vs placebo Pain intensity VAS score0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 7 studies · 297 participants | Low |
Intervention NR Adverse events 1 mg morphine vs 2 mg morphinePercentage of participants with any adverse event · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Pain intensity VAS score1 mg morphine vs 4 mg/5 mg morphine 0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 2 studies · 67 participants | Low |
Intervention NR Pain intensity VAS score1 mg morphine vs 4 mg/5 mg morphine 0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 2 studies · 67 participants | Low |
Intervention NR Pain intensity VAS score1 mg morphine vs 4 mg/5 mg morphine 0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 2 studies · 67 participants | Low |
Intervention NR Analgesia duration 1 mg morphine vs 4 mg/5 mg morphinetime duration from the end of surgery to the first time of analgesic consumption · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 1 study · 24 participants | Moderate |
Intervention NR Adverse events 1 mg morphine vs 4 mg/5 mg morphinePercentage of participants with any adverse event · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | NR | No studies |
IA morphine vs IM morphine Pain intensity VAS score0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 2 studies · 72 participants | Very low |
IA morphine vs IM morphine Pain intensity VAS score0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 2 studies · 72 participants | Low |
IA morphine vs IM morphine Pain intensity VAS score0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 1 study · 39 participants | Low |
IA morphine vs IM morphine Analgesia durationtime duration from the end of surgery to the time of first analgesic consumption. Scale from: 0 to 100. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | NR | No studies |
Morphine vs placebo Pain intensity VAS score0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 7 studies · 297 participants | Low |
IA morphine vs IM morphine Adverse eventsPercentage of participants with any adverse event · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | NR | No studies |
Morphine vs placebo Analgesia durationTime duration from the end of surgery to the time of first analgesic consumption. Scale from: 0 to 100. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 3 studies · 124 participants | Low |
Morphine vs placebo Adverse eventsPercentage of participants with any adverse event · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | RR 1.09 [0.51, 2.36] | 8 studies · 314 participants | Low |
Morphine vs bupivacaine Pain intensity VAS score0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 5 studies · 248 participants | Low |
Morphine vs bupivacaine Pain intensity VAS score0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 6 studies · 330 participants | Low |
Morphine vs bupivacaine Pain intensity VAS score0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 5 studies · 270 participants | Low |
Morphine vs bupivacaine Analgesia durationTime duration from the end of surgery to the time of first analgesic consumption. Scale from: 0 to 100. · patients undergoing knee arthroscopy Single dose intra‐articular morphine for pain control after knee arthroscopy (2016) · Cochrane | no estimate extracted | 3 studies · 162 participants | Moderate |
Bed rest vs ambulation Post‐dural puncture headacheReported by participant · Participants undergoing lumbar puncture Posture and fluids for preventing post‐dural puncture headache (2016) · Cochrane | RR 1.24 [1.04, 1.48] | 12 studies · 1519 participants | Moderate |
Bed rest vs ambulation Severe post‐dural puncture headacheReported by participant · Participants undergoing lumbar puncture Posture and fluids for preventing post‐dural puncture headache (2016) · Cochrane | RR 0.98 [0.68, 1.41] | 9 studies · 1568 participants | Low |
Bed rest vs ambulation Any headacheReported by participant · Participants undergoing lumbar puncture Posture and fluids for preventing post‐dural puncture headache (2016) · Cochrane | RR 1.16 [1.02, 1.32] | 18 studies · 2477 participants | Moderate |
Neuromuscular electrical stimulation (NMES) vs control Quadriceps muscle strength Handheld or fixed dynamometry · adults with advanced disease for muscle weakness Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease (2016) · Cochrane | no estimate extracted | 12 studies · 781 participants | Low |
Neuromuscular electrical stimulation (NMES) vs control Safety Serious adverse events · adults with advanced disease for muscle weakness Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease (2016) · Cochrane | no estimate extracted | 18 studies · 933 participants | Moderate |
Neuromuscular electrical stimulation (NMES) vs control Safety Adverse events: Muscle discomfort · adults with advanced disease for muscle weakness Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease (2016) · Cochrane | no estimate extracted | 18 studies · 933 participants | Moderate |
Neuromuscular electrical stimulation (NMES) vs control Muscle mass Anthropometry, DEXA, ultrasound, computed tomography · adults with advanced disease for muscle weakness Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease (2016) · Cochrane | no estimate extracted | 8 studies · 314 participants | Very low |
Neuromuscular electrical stimulation (NMES) vs control Exercise performance ‐ walking distance 6MWT, ISWT, ESWT · adults with advanced disease for muscle weakness Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease (2016) · Cochrane | no estimate extracted | 13 studies · 788 participants | Very low |
Neuromuscular electrical stimulation (NMES) vs control Exercise performance ‐ peak oxygen uptake · adults with advanced disease for muscle weakness Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease (2016) · Cochrane | no estimate extracted | 4 studies · 109 participants | Low |
Massage vs no massage Pain (PPI‐VAS) · people with cancer Massage with or without aromatherapy for symptom relief in people with cancer (2016) · Cochrane | no estimate extracted | 1 study · 72 participants | Very low |
Aromatherapy massage vs no massage Anxiety (STAI‐state) subgroup: short‐term vs. medium‐term ‐ short‐term (≤ 4 weeks) · people with cancer Massage with or without aromatherapy for symptom relief in people with cancer (2016) · Cochrane | no estimate extracted | 1 study · 32 participants | Very low |
Aromatherapy massage vs no massage Anxiety (STAI‐state) subgroup: short‐term vs. medium‐term ‐ medium‐term (> 4 weeks to < 8 weeks) · people with cancer Massage with or without aromatherapy for symptom relief in people with cancer (2016) · Cochrane | no estimate extracted | 1 study · 221 participants | Moderate |
Aromatherapy massage vs no massage Symptoms relating to the breast (EORTC QLQ‐BR23): long‐term (≥ 8 weeks) · people with cancer Massage with or without aromatherapy for symptom relief in people with cancer (2016) · Cochrane | no estimate extracted | 1 study · 86 participants | Very low |
Aromatherapy massage vs no massage Quality of life (MYMOP): medium‐term (> 4 weeks to < 8 weeks) · people with cancer Massage with or without aromatherapy for symptom relief in people with cancer (2016) · Cochrane | no estimate extracted | 1 study · 29 participants | Very low |
Massage vs no massage Anxiety (STAI‐state) · people with cancer Massage with or without aromatherapy for symptom relief in people with cancer (2016) · Cochrane | no estimate extracted | 3 studies · 98 participants | Very low |
Massage vs no massage Anxiety (STAI‐state) subgroup 1: children vs. adults ‐ children · people with cancer Massage with or without aromatherapy for symptom relief in people with cancer (2016) · Cochrane | no estimate extracted | 1 study · 30 participants | Very low |